1. A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies. (24th February 2016) Authors: Emery, P; McInnes, I; Genovese, MC; Smolen, JS; Kremer, J; Dougados, M; Schlichting, DE; Rooney, T; Issa, M; de Bono, S; Macias, WL; Rogai, V; Zuckerman, SH; Taylor, PC Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study. (15th June 2017) Authors: Takeuchi, T; Fleischmann, R; Schiff, M; Issa, M; Macias, W; Rooney, T; Zuckerman, S; Schlichting, D; McInnes, I Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus. (27th September 2022) Authors: Liu-Walsh, F; Van Hartingsveldt, B; Zuraw, Q; Hoffman, RW; Rooney, T; Gao, S; Gordon, R; Leu, JH; Berhanu Debella, A; Calderon, C; Zazzetti, F; Vratsanos, G Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0058 Effects of baricitinib on patients who stop methotrexate monotherapy and switch to baricitinib monotherapy. (15th June 2017) Authors: Fleischmann, R; Takeuchi, T; Schiff, M; Schlichting, D; Xie, L; Issa, M; Stoykov, I; Lisse, JR; Martinez-Osuna, P; Rooney, T; Zerbini, CA Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 789 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0072 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. (15th June 2017) Authors: Takeuchi, T; Genovese, M; Haraoui, B; Xie, L; Klar, R; Correia, A Luisa Pinto; Rooney, T; Otawa, S; Smolen, JS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 795 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Issue 11 (12th October 2004) Authors: Rooney, T; Murphy, E; Benito, M; Roux-Lombard, P; FitzGerald, O; Dayer, J-M; Bresnihan, B Journal: Annals of the rheumatic diseases Issue: Volume 63:Issue 11(2004) Page Start: 1393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗